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Purpose: This study was performed to describe and evaluate the management of male lower urinary tract symptoms (LUTS) 
suggestive of benign prostatic hyperplasia (BPH) by general practitioners (GPs) in Jakarta.
Methods: This observational cross-sectional study was peformed between January 2013 and August 2013 in Jakarta. We developed 
a questionnaire consisting of 10 questions describing the management of male LUTS suggestive of BPH by GPs in their daily practice in 
the previous month. We collected questionnaires from 200 GPs participating in 4 urology symposiums held in Cipto Mangunkusumo 
Hospital, Jakarta. 
Results: Most GPs were aged between 25 and 35 years (71.5%) and had worked for more than 1 year (87.5%). One to 5 cases of male 
LUTS suggestive of BPH were treated by 81% of GPs each month. At diagnosis, the most common symptoms found were urinary 
retention (55.5%), frequency (48%), and nocturia (45%). The usual diagnostic workup included digital rectal examination (65%), 
scoring system (44%), measurement of prostate-specific antigen (PSA) level (23.5%), and renal function assessment (20%). Most GPs 
referred their male patients with LUTS suggestive of BPH to a urologist (59.5%) and 46.5% of GPs prescribed drugs as an initial therapy. 
Alpha-adrenergic antagonist monotherapy (71.5%) was the most common drug prescribed. Combination therapy with α-adrenergic 
antagonists and 5α-reductase inhibitors was not routinely prescribed (13%). Thirty-eight percent of GPs referred their patients when 
recurrent urinary retention was present and 33% when complications were present.
Conclusions: Our study provides evidence that the management of male LUTS suggestive of BPH by GPs in Jakarta suggests referral 
in part to available guidelines in terms of diagnostic methods and initial therapy. However, several aspects of the guidelines, such as 
PSA level measurement, renal function assessment, urinalysis, ultrasound examination, and prescription of combination therapies, are 
still infrequently performed. 
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INTRODUCTION
 
Benign prostatic hyperplasia (BPH) is the most common 
urological condition, and benign enlargement in men older 
than 50 years of age is becoming an important issue in gen-
eral practice owing to the increasing number of aging men 
[1]. BPH is a pathologic process that contributes to, but is not 
the sole cause of, lower urinary tract symptoms (LUTS) and 
for which age and the patient’s hormonal status are proven 
as risk factors [2,3]. The incidence and prevalence of BPH 
increases with age until the age of 80 years [4]. Hyperplasia 
usually starts to develop in the glandular and fibromuscular 
tissue of the prostate from 30 to 40 years of age and continues 
from 50 to 60 years of age [1].
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symptoms of the patients, initial diagnostic workup, the most 
common scoring system used, initial therapy, initial drugs 
prescribed, time to follow-up, evalution at follow-up, referral 
criteria, common α-adrenergic antagonists prescribed, and 
common α-adrenergic antagonist-related side effects. De-
scriptive analysis was provided for each question.  
RESULTS
1. Characteristics of GPs
We collected data from a total of 200 GPs. Most of the GPs 
were aged from 25 to 35 years (71.5%) and had worked for 
more than 1 year. These GPs worked in clinics (55.5%), hos-
pitals (36%), and general primary care (8.5%). Most of them 
(81%) dealt with 1 to 5 men with LUTS suggestive of BPH 
each month (Table 1).
2. Diagnosis of male LUTS suggestive of BPH
We found that the most common symptoms were urinary 
retention (55.5%), followed by frequency (48%) and nocturia 
(45%) (Fig. 1). The usual diagnostic workup performed in-
cluded DRE (65%), scoring system (44%), PSA level measure-
ment (23.5%), and renal function assessment (20%). Urinaly-
sis and abdominal ultrasound were performed by only 19% 
and 17% of GPs, respectively. Imaging study was not routinely 
 Bothersome LUTS are associated with a negative impact on 
quality of life (QoL) [5]. Impairment of QoL is mostly caused 
by nocturia and a weak urinary stream [6]. The validity of 
simple diagnostic tools such as medical history, International 
Prostate Symptom Score (IPSS), digital rectal examination 
(DRE), and measurement of the serum prostate-specific 
antigen (PSA) level has been proven in studies such as the di-
agnosis improvement in primary care trial (D-IMPACT) study 
[7]. However, in a study performed by Fourcade et al. [8], only 
less than half of men who presented with LUTS suggestive of 
BPH were diagnosed by use of a standardized assesment by 
GPs. Treatment decisions should be based on the patient’s 
QoL as measured by questionnaires such as the IPSS to as-
sess the impact of the LUTS on psychological well-being and 
social activity [9,10].
 The progressive development of conservative therapy for 
male LUTS suggestive of BPH has shifted the paradigm of 
LUTS management. Patients without bothersome symptoms 
and signs of complications can be offered watchful waiting 
therapy [11]. Conservative treatment is preferred for men 
with moderate to severe LUTS without absolute indications 
for invasive treatment [9,10,12]. General practioners now 
have a wider role owing to increased numbers of conservative 
management options such as use of α-adrenergic antagonists 
and 5α-reductase inhibitors (5-ARIs). These drugs have been 
known to improve LUTS and reduce serious complications 
in BPH patients such as acute urinary retention, urinary tract 
infection, and decreased renal function; hence, they may 
improve patients’ QoL and reduce the risk of these complica-
tions [5].
 The main objective of this observational study was to 
desribe the management of male LUTS suggestive of BPH, 
including diagnostic measures and treatment, by GPs in 
Jakarta. We then evaluated whether this particular manage-
ment pattern adhered to available guidelines.
MATERIALS AND METHODS
This observational cross-sectional study was peformed be-
tween January and August 2013. We collected questionnaires 
from 200 GPs participating in 4 urology symposiums for GPs 
held in Cipto Mangunkusumo Hospital in Jakarta. The ques-
tionnaires were self-administered by the GPs. All of the par-
ticipants worked in Jakarta. 
 We developed a questionnaire consisting of 10 items on 
the management of male LUTS suggestive of BPH in the daily 
practice of GPs in the previous month. Included in the ques-
tionnaire were characteristics of the GPs, the most common 
Table 1. Characteristic of general practitioners (n=200)
Characteristic No. (%)
Age (yr)
25–30 119 (59.5)
31–35 24 (12.0)
36–40 19 (9.5)
41–45 12 (6.0)
46–50 12 (6.0)
>50 14 (7.0)
Workplace
Clinic 95 (47.5)
Hospital 72 (36.0)
General primary care 17 (8.5)
Others 16 (8.0)
Length of practice (yr)
<1 25 (12.5)
1–2 68 (34.0)
3–5 32 (16.0)
>5 75 (37.5)
No. of BPH patient (each month)
1–5 162 (81.0)
6–10 16 (8.0)
11–20 17 (8.5)
>20 5 (2.5)
BPH, benign prostatic hyperplasia.
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done. The IPSS was the most common scoring system used in 
diagnosing male LUTS suggestive of BPH (61%) (Table 2).
3. Treatment of male LUTS suggestive of BPH
Our findings showed that most GPs referred their patients to 
a urologist (59.5%), and 46.5% prescribed drugs as an initial 
therapy. Alpha-adrenergic antagonist monotherapy (71.5%) 
was the most common drug prescribed. Combination thera-
py of α-adrenergic antagonists and 5-ARIs was not routinely 
given (13%). Dizzinesss (33%) and orthostatic hypotension 
(26.5%) were the most common side effects found. The pa-
tients were followed up 2 weeks after treatment by 80.5% of 
GPs. On follow-up, most GPs performed a DRE (33.5%) and 
monitoring of drug side effects (32.5%) (Table 3). Among the 
criteria for referral to a urologist, 38% of GPs referred patients 
when recurrent urinary retention was present and 33% when 
complications were present (Fig. 2).
DISCUSSION
The results of the present study showed that urinary reten-
tion was the most common symptom (55.5%) that brought 
patients to a GP. Contrary to this finding, urinary retention 
was not a common symptom reported by GPs in a survey per- 
formed by Montorsi and Mercadante [6] of GPs in France, 
Germany, Italy, Spain, and the United Kingdom. Urinary re-
tention was found in only 6.8% of BPH cases. This difference 
is probably because patients’ awareness of BPH symptoms 
and compliance with a routine medical checkup are higher 
Table 2. Diagnostic workup of male LUTS suggestive of BPH 
(n=200)
Variable No. (%)
Initial Diagnostic workupa)
Scoring system 88 (44.0)
Digital rectal examination 130 (65.0)
Urinalysis 38 (19.0)
Renal function 40 (20.0)
Prostate-specific antigen 47 (23.5)
Uroflowmetry 9 (4.5)
Abdominal USG 34 (17.0)
BNO cystogram 2 (1.0)
BNO IVP 18 (9.0)
Others 13 (6,5)
Length to follow-up
2 Weeks 161 (80.5)
1 Month 25 (12.5)
2 Month 1 (0.5)
Others 13 (6.5)
Diagnostic workup at follow-upa)
Scoring system 1 (0.5)
Digital rectal examination 67 (33.5)
Urinalysis 34 (17.0)
Prostate-specific antigen level 20 (10.0)
Uroflowmetry 12 (6.0)
Side effects 65 (32.5)
Others 8 (4.0)
LUTS, lower urinary tract symptoms; BPH, benign prostatic hyperplasia; 
USG, ultrasonography; BNO IVP, blass nier overzicht intravenous pyelo-
gram.
a)Answer can be more than 1 option.
Fig. 1. Symptoms of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH).
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in Europe than in Indonesia, where BPH patients tend to seek 
medical help when severe symptoms or complications are 
already present. Urinary retention is one of the most common 
complications of male LUTS suggestive of BPH and becomes 
one of the indications for surgery [9,10]. Both delay in diagno-
sis and ineffective treatment are responsible for urinary reten-
tion episodes. 
 Frequency and nocturia were also common symptoms 
in our study. A similar result was described by Montorsi and 
Mercadante [6], who showed that nocturia was the most com-
mon symptom (77%). The triad of nocturia-frequency-feeling 
of incomplete emptying (22.6%) was the most common sym 
ptom combination. A study performed by Hernandez et al. 
[13] in Spain also showed that nocturia was the most common 
symptom in male LUTS suggestive of BPH in patients more 
than 60 years of age. Nocturia, frequency, and incomplete 
emptying were also the most common symptoms found in 
the epidemiology of LUTS (EpiLUTS) study performed in the 
United States, the United Kingdom, and Sweden [14]. Both 
frequency and nocturia are crucial, especially in elderly, be-
cause these symptoms are associated with an increased risk 
of falls [6]. Nocturia is also correlated with a lower QoL, which 
is reflected by worsening quality of sleep, reduced energy lev-
els, and increased bother and concern [13].
 In this study, DRE, scoring system, renal function assess-
ment, PSA level measurement, urinalysis, and ultrasound 
were not routinely done by GPs in men with LUTS suggestive 
of BPH. These results are similar to those of a study in several 
countries in Europe that showed that the IPSS questionna- 
Fig. 2. Referral criterias of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH). PSA, prostate-specific 
antigen.
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Table 3. Treatment of male LUTS suggestive of BPH (n=200)
Variable No. (%)
Intial therapya)
Drugs 93 (46.5)
Refer 119 (59.5)
Watchful waiting 37 (18.5)
Others 9 (4.5)
Drugs
α-Adrenergic antagonists 143 (71.5)
5-ARI 11 (5.5)
α-Adrenergic antagonists + 5-ARI 18 (9.0)
α-Adrenergic antagonists + 5-ARI in large volume 
   prostate
8 (4.0)
α-Adrenergic antagonists + 5-ARI + antimuscarinic 13 (6.5)
Phytotherapy 7 (3.5)
α-Adrenergic antagonists
Tamsulosin 129 (64.5)
Terazosin 29 (14.5)
Doxazosin 19 (9.5)
Alfuzosin 6 (3.0)
Others 2 (1.0)
Without α-adrenergic antagonists 15 (7.5)
Side effect of α-adrenergic antagonistsa)
Asthenia 22 (11.0)
Dizziness 66 (33.0)
Orthosatic hypotension 53 (26.5)
Erectile dysfunction 19 (9.5)
Abnormal ejaculation 4 (2.0)
Others 4 (2.0)
LUTS, lower urinary tract symptoms; BPH, benign prostatic hyperplasia; 
5-ARI, 5α-reductase inhibitor.
a)Answer can be more than 1 option.
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ire only was used by 3.2% to 14.5% of GPs, except in Spain 
(57.1%). DRE only was performed by 20% of GPs in Italy; uri-
nalysis by 34% of GPs in France [6]. Fourcade et al. [8,15] in 
two separate studies in Europe also showed that only a small 
number of GPs performed IPSS, DRE, and PSA measurement 
to diagnose male LUTS suggestive of BPH. According to cur-
rent guidelines, minimum diagnostic workups of men with 
LUTS suggestive of BPH include evaluation of symptoms 
(IPSS questionnaire), DRE, frequency-volume chart, urinaly-
sis, and PSA level measurement [9,10]. Our BPH manage-
ment guidelines in Indonesia also recommend performing 
the IPSS questionnaire, DRE, frequency-volume chart, PSA 
level measurement, renal function assessment, and urinaly-
sis to diagnose LUTS suggestive of BPH [12]. The D-IMPACT 
study showed that age, IPSS, and PSA level measurement 
were accurate for diagnosis with a positive predictive value of 
75% and were easily implemented in any GP office [7]. One 
reason for the low use of the IPSS questionnaire was prob-
ably because it was considered to be impractical and too time 
consuming, especially in a busy primary care setting [16,17]. 
Renal function assessment and PSA level measurement were 
not routinely performed, probably because of cost and lack 
of a facility to perform it in the primary care setting. Assess-
ment of PSA, renal function, and urinalysis are very impor-
tant because abnormal renal function, high PSA suggestive 
of prostate cancer, and recurrent urinary tract infection are 
indications for referral of a male patient with LUTS sugges-
tive of BPH to a urologist. A frequency-volume chart is also 
an important diagnostic tool to see and assess objectively the 
patient’s symptoms. One limitation of our study is that we did 
not include a frequency-volume chart as one of the diagnostic 
options. The limited knowledge of GPs of the current guide-
lines is one possible explanation for this discrepancy. 
 Most GPs still referred BPH cases without prescribing an 
initial therapy. This may be because most patients presented 
with urinary retention. The GPs who prescribed an intial the- 
rapy usually put their patients on α-adrenergic antagonist 
monotherapy. On the other hand, combination therapy was 
less likely to be prescribed. A study of GPs in France showed 
an unsatisfactory outcome in half of medically treated male 
patients with LUTS suggestive of BPH, which suggested unef-
fective medical treatment by GPs. Most patients were treated 
with monotherapy, either α-adrenergic antagonists, 5-ARIs, or 
plant extracts (58.1%). Only 13% of patients were treated with 
combination therapies [15].
 According to current guidelines, medical treatment of male 
 LUTS suggestive of BPH can be prescribed by GPs. How-
ever, most GPs were likely not confident in prescribing drugs 
for these patients. Alpha-adrenergic antagonists are the 
first-line treatment of LUTS [9,10,12]. The combination of 
an α-adrenergic antagonist and 5-ARI is effective for BPH 
treatment, which was suggested by the Medical Therapy of 
Prostatic Symptoms (MTOPS) study (finasteride-doxazosin) 
and the Combination of Avodart and Tamsulosin (CombAT) 
study (dutasteride-tamsulosin) [18,19]. This combination 
therapy is suggested for BPH patients with a high prostate 
volume. Transabdominal ultrasonography can be performed 
to estimate prostate volume when transrectal ultrasonogra-
phy is not available. In this study, only 17% of GPs performed 
abdominal ultrasound. The difficulty in estimating prostate 
volume by using DRE and the lack of ultrasound machines in 
the primary care setting with which to measure prostate vol-
ume are possible explanations for the low rate of prescription 
of combination therapy by GPs. These obstacles should be 
taken into consideration when formulating and introducing 
new guidelines in the future.
 DRE and evaluation of side effects of the drugs prescribed 
were commonly performed at follow-up, which usually took 
place 2 weeks after treatment. This short time to follow-up is 
one discrepancy between the GPs’ management of LUTS and 
the available guidelines. On the basis of both the European 
Association of Urology and the Indonesian guidelines, watch-
ful waiting patients should be followed up at 6 months and 
patients with medical treatments at 4 to 6 weeks [9,12]. The 
GPs’ low awareness of the available guidelines is a possible 
explanation for this finding. Dizzinesss and orthostatic hypo-
tension were the most common α-adrenergic antagonist-re-
lated side effects found in our study. Orthostatic hypotension 
is one of the main side effects of α-adrenergic antagonists 
because it increases the risk of falls [6]. The cardiovascular 
effect of α-adrenergic antagonists prescribed for male LUTS 
suggestive of BPH should also raise caution because there is 
an association between LUTS and metabolic syndrome and 
vascular risk factors [7,8,20]. 
 We found that the most common referral criteria were rec- 
urrent urinary retention and presence of complications. 
These referral criteria are concurrent with current guidelines 
[9,10,12,21]. We also found that 38% of GPs still referred all 
suggestive BPH cases. This may be explained by the high 
number of cases with urinary retention in our study, whom 
GPs were still not confident in treating.
 We can conclude that the findings of our study were not 
due to recruitment of a particular subgroup of GPs such as 
young or inexperienced GPs, because most of the participants 
had worked for more than 1 year. One limitation of this study 
was that we did not define the exact numbers of GPs who had 
Matondang and Rahardjo. Male LUTS suggestive of BPH management by general practitioners
102
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14040
worked for more than 5 years. Therefore, we cannot exclude 
the extreme group that may not pay attention to guidelines 
for male LUTS suggestive of BPH. Another limitation of our 
study was that GPs cannot make a definite diagnosis of the 
cause of LUTS. Male LUTS can be caused by other diseases 
such as overactive bladder. For a definite diagnosis of BPH, a 
histopathology examination is needed.
 Our study describes the management pattern of male LUTS 
suggestive of BPH by GPs and shows that the pattern does 
not completely comply with available guidelines. This should 
encourage more efforts to improve the awareness of GPs of 
the guidelines. The facilities available in primary care settings 
should also be a consideration when formulating revised gu- 
idelines. A clear description of the roles of GPs and urologists 
in the management of BPH should also be included. 
 In conclusion, our study provided evidence that the man-
agement of male LUTS suggestive of BPH by GPs in Jakarta in 
part complied with current guidelines in terms of diagnostic 
and initial therapy. However, several aspects of the guidelines, 
such as PSA level measurement, renal function assessment, 
urinalysis, ultrasound, and prescription of combination ther-
apies, were still infrequently performed. The follow-up period 
was also shorter than advised. GPs should be introduced to 
and reminded of the management guidelines for male LUTS 
suggestive of BPH. 
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